Mammary Cell News 9.34 August 31, 2017 | |
| |
TOP STORYZ-Endoxifen Shows Promise as New Treatment for Common Breast Cancer Type The final results of a first-in-human Phase I study of Z-endoxifen in women with estrogen receptor positive metastatic breast cancer showed that the treatment was safe and resulted in tumor shrinkage in women whose tumors had progressed on standard anti-estrogen therapies, including tamoxifen. [Press release from the Mayo Clinic discussing online prepublication in Journal of Clinical Oncology] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHScientists identified transmembrane glycerophosphodiesterase GDE3 as a glycosylphosphatidylinositol (GPI)-specific phospholipase C that cleaves and releases urokinase receptor (uPAR) with consequent loss of function, whereas its homologue GDE2 fails to attack uPAR. GDE3 overexpression depleted uPAR from distinct basolateral membrane domains in breast cancer cells, resulting in a less transformed phenotype, it slowed tumor growth in a xenograft model and correlated with prolonged survival in patients. [eLife] Full Article The authors investigated the role of C-reactive protein (CRP) in the adhesive phenotype of breast cells and the underlying mechanisms. They showed that CRP induces adhesion of MCF10A human breast epithelial cells through the activation of integrin α2 signaling. [Oncogene] Abstract Neoadjuvant Interferons: Critical for Effective PD-1 Based immunotherapy in TNBC Investigators demonstrated an interplay between type I IFN signaling and tumor cell PD-L1 expression that impacted therapeutic response. The data revealed that the type I IFN-inducer poly(I:C) was an effective immune activator and antimetastatic agent, functioning better than anti-PD-1, which was ineffective as a single agent. [Cancer Immunol Res] Abstract The authors showed that peptidylargininedeiminase 1 (PAD1) is overexpressed in human triple negative breast cancer (TNBC). In cultured cells and xenograft mouse models, PAD1 depletion or inhibition reduced cell proliferation, suppressed epithelial-mesenchymal transition, and prevented metastasis of MDA-MB-231 cells. [Cancer Lett] Abstract The anti-cancer effects, as well as the detailed mechanisms of isoliquiritigenin, were explored. Researchers verified the anti-cancer effect of isoliquiritigenin on migration and invasion, and identified highly expressed miR-374a as one of the main microRNAs down-regulated by isoliquiritigenin treatment in breast cancer. [Sci Rep] Full Article TGF-β1 Induces EMT in Bovine Mammary Epithelial Cells through the TGFβ1/Smad Signaling Pathway Bovine mammary epithelial cells (BMECs) were treated with TGF-β1, and epithelial-mesenchymal transition (EMT)-related gene and protein expression changes were evaluated using quantitative real-time polymerase chain reaction, western blotting, and immunofluorescence. The TGF-β1 level was up-regulated in mammary tissues with mastitis and in inducible inflammatory BMECs. [Cell Physiol Biochem] Full Article ATM Is Required for SOD2 Expression and Homeostasis within the Mammary Gland Researchers examined if the NF-κB target gene and critical antioxidant SOD2 in cultured mammary epithelium is also ATM-dependent, and what phenotypes arise from deletion of ATM and SOD2 within the mammary gland. [Breast Cancer Res Treat] Abstract ERRα Regulates the Growth of Triple-Negative Breast Cancer Cells via S6K1-Dependent Mechanism Scientists focused on investigating the biochemical relationship between estrogen-related receptor alpha (ERRα) and S6K1. They found that ERRα negatively regulates S6K1 expression by directly binding to its promoter. [Signal Transduct Target Ther] Full Article CLINICAL RESEARCHPre-specified analysis of five DNA repair deficiency biomarkers was performed on 116 HER2− patients. Researchers evaluated the 70-gene ultra-high risk signature (MP1/2), one of the biomarkers used to define subtype in the trial. [npj Breast Cancer] Full Article | |
| |
REVIEWSEstrogen and Progesterone Signaling in the Normal Breast and Its Implications for Cancer Development The authors summarize current knowledge of the mechanisms of action of nuclear estrogen and progesterone receptors in the normal breast, and implications for the development and management of breast cancer. [Mol Cell Endocrinol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSPuma Biotechnology Announces Publication of Abstracts Puma Biotechnology, Inc. announced the release of two abstracts on its drug neratinib that will be presented. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab in women with early stage HER2-positive breast cancer. [Press release from Puma Biotechnology, Inc discussing research to be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, Madrid] Press Release New Phase III Data for Abemaciclib and Ramucirumab Presented Results from Phase III studies of abemaciclib and ramucirumab have been selected for oral presentation during a Presidential Symposium, which features groundbreaking research that is potentially practice-changing. [Press release from Eli Lilly and Company discussing research to be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, Madrid] Press Release | |
| |
INDUSTRY NEWSBristol-Myers Squibb Company and Daiichi Sankyo Company, Limited announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial cancers. [Bristol-Myers Squibb Company] Press Release Daiichi Sankyo Company, Limited announced the initiation of DESTINY-Breast01, a pivotal Phase II study evaluating the safety and efficacy of investigational HER2-targeting antibody drug conjugate DS-8201 in patients with HER2-positive unresectable and/or metastatic breast cancer resistant or refractory to ado-trastuzumab emtansine. [Daiichi Sankyo Company, Limited] Press Release AstraZeneca announced that the FDA has approved Faslodex as monotherapy for use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer who are postmenopausal and have not received previous endocrine therapy. [AstraZeneca] Press Release | |
| |
POLICY NEWSScience Suffers as China’s Internet Censors Plug Holes in Great Firewall China is tightening the screws on internet access, again. The latest crackdown—an evolving effort to ban virtual private networks not under government control—could seriously erode scientists’ ability to stay connected with peers abroad. [ScienceInsider] Editorial The FDA has taken steps in Florida and California to address a number of especially troubling products being marketed. But unfortunately, these are examples of a larger pool of actors who claim that their unproven and unsafe products will address a serious disease, but instead put patients at significant risk. [U.S. Food and Drug Administration] Editorial FDA Warns US Stem Cell Clinic of Significant Deviations The U.S. FDA posted a warning letter issued to US Stem Cell Clinic of Sunrise, Florida, and its Chief Scientific Officer Kristin Comella for marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements, including some that could impact the sterility of their products, putting patients at risk. [U.S. Food and Drug Administration] Editorial
| |
EVENTSNEW 51st Miami Winter Symposium Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Mammary Gland Stem Cells (Université Libre de Bruxelles) Postdoctoral Training Fellows – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Position – Mammary Tumors (Cancer Research UK Beatson Institute) Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Clinician Investigator – Breast Cancer Research (Mayo Clinic) Research Fellows – Cancer Research (National University of Singapore) Multiple Positions – Cancer Research (National University of Singapore) Postdoctoral Position – Breast Cancer Research (Massachusetts General Hospital Cancer Center) PhD Student – Breast Cancer Biology (VIB-KULeuven Center for Cancer Biology) Associate Medical Director/Medical Director – Breast Cancer (Genentech, Inc.) Postdoctoral Fellow – Cancer Research (University of Texas Health Science Center at San Antonio) Postdoctoral Fellow – Cancer Genomics (University of Texas Health Science Center at Houston) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 9.34 | Aug 31 2017